title: [Helicobacter pylori infection--clinical aspects and indications for treatment].
abstract: Helicobacter pylori (H. p.) causes active chronic antrum gastritis in all infected patients. In a relatively small percentage complications of H. p.-gastritis including duodenal ulcer, gastric ulcer, giant fold gastritis, lymphocytic gastritis, autoimmune gastritis, gastric carcinoma and gastric MALT lymphoma may develop. Strongly recommended indications for eradication therapy include gastroduodenal ulcer disease, giant fold gastritis, lymphocytic gastritis, autoimmune gastritis, gastric MALT lymphoma, atrophic gastritis, corpus-predominant gastritis, post gastric cancer resection and patients who are first degree relatives of gastric cancer patients. Eradication therapy is controversial in patients with gastroesophageal reflux disease, functional dyspepsia and in patients in whom treatment with nonsteroidal antiinflammatory drugs (NSAID) or long-term treatment with proton pump inhibitors (PPI) is planned.
authors: 4. Medizinische Abteilung, Krankenanstalt Rudolfstiftung, Juchgasse 25, A-1030 Wien. Michael.Gschwantler@kar.magwien.gv.at
authors: M
authors: M
authors: Gschwantler
authors: M
authors: M
authors: Bischof
authors: Elisabeth
authors: E
authors: Singer
authors: W
authors: W
authors: Weiss
mesh_terms: D000897:Anti-Ulcer Agents / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D016481:Helicobacter Infections / Q000175:diagnosis* / Q000188:drug therapy; D016480:Helicobacter pylori; D006801:Humans; D012008:Recurrence; D013272:Stomach Diseases / Q000175:diagnosis* / Q000188:drug therapy
chemical_list: D000897:Anti-Ulcer Agents